BAUSCH+ Health

Third Quarter 2022 Earnings Call

November 3, 2022

Forward-looking statements

This presentation contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, "forward-looking statements"), including, but not limited to, statements relating to Bausch Health Companies Inc.'s ("Bausch Health" or the "Company") future prospects and performance, financial guidance, proposed plan to fully separate its eye health business, including the timing thereof, anticipated impact of its debt exchange and management of its balance sheet, generation of cash, ability to launch and commercialize new products, anticipated launch of new products, including the number of such new products, geographic locations and timing for launch; ability to enforce and defend its Xifaxan® intellectual property rights, and other corporate and strategic transactions. Forward-looking statements may generally be identified by the use of the words "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and positive and negative variations or similar expressions, and phrases or statements that certain actions, events or results may, could, should or will be achieved, received or taken, or will occur or result, and similar such expressions also identify forward-looking information. These forward-looking statements, including the Company's full-year guidance, are based upon the current expectations and beliefs of management and are provided for the purpose of providing additional information about such expectations and beliefs, and readers are cautioned that these statements may not be appropriate for other purposes. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in the Company's most recent annual and quarterly reports and detailed from time to time in the Company's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which risks and uncertainties are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties relating to the Company's proposed plan to fully separate its eye health business from the remainder of Bausch Health. In particular, the Company can offer no assurance that any spinoff transaction will occur at all, or that any spinoff or other separation transaction will occur on the terms and timelines anticipated by the Company. They also include risks and uncertainties related to the uncertainty of commercial success for new and existing products; challenges to patents; challenges to the Company's ability to enforce and defend against challenges to its patents; the impact of patent expirations and the ability of the company to successfully execute strategic plans.

They also include risks and uncertainties related to the challenges the Company faces as a result of the closing of the initial public offering ("IPO") of Bausch + Lomb Corporation ("Bausch + Lomb"), including the transitional services being provided by and to Bausch + Lomb, any potential actual or perceived conflict of interest of some of our directors and officers because of their equity ownership in Bausch + Lomb and/or because they also serve as directors or officers of Bausch + Lomb and our ability to timely consolidate the financial results of the Bausch + Lomb business. They also include, but are not limited to, risks and uncertainties caused by or relating to the COVID-19 pandemic, the fear of that pandemic, the availability and effectiveness of vaccines for COVID-19, (including current or future variants and subvariants), COVID-19 vaccine immunization rates, the emergence of variant and subvariant strains of COVID-19, and the potential effects of that pandemic, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on the Company. They also include economic factors, such as interest rate, inflation rate and currency exchange rate fluctuations, and competition, including technological advances, new products and patents attained by competitors.

Additional information regarding certain of these material factors and assumptions may be found in the Company's filings described above. The Company believes that the material factors and assumptions reflected in these forward-looking statements are reasonable in the circumstances, but readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this presentation or to reflect actual outcomes, unless required by law.

The guidance in this presentation is only effective as of the date given and will not be updated or affirmed unless and until the Company publicly announces updated or affirmed guidance. Distribution or reference of this presentation following the date of this presentation does not constitute the Company re-affirming guidance.

Non-GAAP information

To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures and ratios to provide supplemental information to readers. Management uses these non-GAAP measures and ratios as key metrics in the evaluation of Company performance and the consolidated financial results and, in part, in the determination of cash bonuses for its executive officers. The Company believes these non-GAAP measures and ratios are useful to investors in their assessment of our operating performance and the valuation of the Company. In addition, these non-GAAP measures and ratios address questions the Company routinely receives from analysts and investors and, in order to assure that all investors have access to similar data, the Company has determined that it is appropriate to make this data available to all investors.

However, these measures and ratios are not prepared in accordance with GAAP nor do they have any standardized meaning under GAAP. In addition, other companies may use similarly titled non-GAAP financial measures and ratios that are calculated differently from the way we calculate such measures and ratios. Accordingly, our non-GAAP financial measures and ratios may not be comparable to such similarly titled non-GAAP measures and ratios. We caution investors not to place undue reliance on such non-GAAP measures and non-GAAP ratios, but instead to consider them with the most directly comparable GAAP measures. Non-GAAP financial measures and non-GAAP ratios have limitations as analytical tools and should not be considered in isolation. They should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP.

The reconciliations of these non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with GAAP are shown in the Appendix hereto. However, for guidance purposes, the Company does not provide reconciliations of projected Adjusted EBITDA (non-GAAP) to projected GAAP net income (loss), projected Adjusted Cash Flows from Operations (non-GAAP) to projected GAAP Cash Generated from Operations, projected Adjusted Gross Margin (non-GAAP) to projected GAAP Gross Margin, projected Adjusted SG&A Expense to projected GAAP SG&A Expense, projected Adjusted Tax Rate to projected GAAP tax rate and projected organic growth (non-GAAP) to projected reported revenue growth, in each case due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations. Many of the adjustments and exclusions used to calculate the projected non-GAAP measures may vary significantly based on actual events, so the Company is not able to forecast on a GAAP basis with reasonable certainty all adjustments needed in order to provide a GAAP calculation of these projected amounts. The amounts of these adjustments may be material and, therefore, could result in the GAAP amount being materially different from (including materially less than) the projected non-GAAP measures.

For further information on non-GAAP financial measures and ratios, please see the Non-GAAP Appendix.

1 Key developments

2 3Q financial results

Agenda

3 FY 2022 guidance

4 Actions taken and path forward

1 Key developments

Key developments[1]

- Delivered sequential sales improvement for Bausch Pharma and Solta this quarter
- Reduced debt principal by $2.5B through very successful debt exchange offer
- Continue to evaluate potential options to maximize value
- Vigorously defend our intellectual property in the Xifaxan® patent litigation

1. See Slide 2 for further information on forward looking statements.

Key actions underway[1]

Salix

- Activate patients and caregivers through targeted commercial strategies
- Establish Xifaxan® as the treatment of choice with tailored HCP[2] campaigns
- Drive improvement in script growth
- Continue to intensify initiatives to improve diagnosis and treatment of GI disease

International

- Grow key markets (Poland, Mexico, Canada) with existing brands and new products
- Expand branded generic product line

Solta Medical

- Drive organic growth across established markets

Diversified Products

- Balance growth opportunities while optimizing profit and cash contribution of mature portfolio
- Branded DTC campaign benefitting Jublia®

1. See Slide 2 for further information on forward-looking statements.
2. HCP = Healthcare provider.

2 Third quarter financial results

Consolidated

3Q22 Revenue

Revenue change vs 3Q21, in millions USD

Bausch Health Consolidated



Reported (3%)

Organic[1] 2%

Bausch Pharma + Solta



Reported (5%)

Organic[1] (1%)

Bausch + Lomb



Reported (1%)

Organic[1] 5%

1. This is a non-GAAP measure or non-GAAP ratio. See Slide 3 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

Unconsolidated

3Q22 Bausch Pharma + Solta revenue

Revenue change vs 3Q21, in millions USD

Salix



Reported **3%**

Organic[1] **3%**

International



Reported **(8%)**

Organic[1] **10%**

Solta Medical[2]



Reported **(3%)**

Organic[1] **4%**

Diversified Products



Reported **(18%)**

Organic[1] **(17%)**

Key drivers

% Reported revenue change

Salix
- Xifaxan® **4%**
- Trulance® **20%**
- Relistor® **25%**
- Plenvu® **60%**

International
- Strong organic performance in Canada and Europe
- Double digit growth in multiple key brands

Solta Medical
- Strong results in Asia Pacific
- Ongoing recovery in Asia Pacific following slow down in first half

Diversified Products
- Wellbutrin® **(9%)**
- Aplenzin® **16%**
- Lower sales from legacy products
- Arestin® **10%**

1. This is a non-GAAP measure or non-GAAP ratio. See Slide 3 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.
2. Solta Medical sales mix during 2Q22 was 65% Consumables and 35% Console.

Unconsolidated

Bausch Pharma + Solta highlights by segment

Revenue change vs 3Q21, in millions USD

Salix

3Q 2022 Revenue: **$544M**

Reported: **3%,** Organic[2]: **3%**

- Xifaxan® TRx[1] growth flat, with positive script growth during the last 8 weeks
- Retail inventory reduction of $13M in Xifaxan®
- Trulance® TRx[1] 6% growth
- Relistor® TRx[1] 22% growth
- Plenvu ® TRx[1] 23% growth

International

3Q 2022 Revenue: **$250M**

Reported: **(8%),** Organic[2]: **10%**

- Strong growth in Canada, EMEA
- Impact from divestitures (Amoun) of ($23M)
- Healthy performance across various key products
- Several upcoming product launches in new markets[3]

Solta Medical

3Q 2022 Revenue: **$72M**

Reported: **(3%),** Organic[2]: **4%**

- Strong performance in Asia Pacific
- China continuing to recover from lockdowns

Diversified Products

3Q 2022 Revenue: **$238M**

Reported: **(18%),** Organic[2]: **(17%)**

- Lower demand for Wellbutrin® and certain products compared to higher COVID-related demand last year
- Aplenzin® TRx[1] 19% growth
- Jublia® TRx[1] 34% growth
- EBITA margin stable over last year

1. TRx = total prescriptions. Source: IQVIA.
2. This is a non-GAAP measure or non-GAAP ratio. See Slide 3 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.
3. See Slide 2 for further information on forward-looking statements.

Unconsolidated

3Q22 Bausch + Lomb revenue

Revenue change vs 3Q21, in millions USD

	Revenue	Vision Care	Surgical	Ophthalmic Pharmaceuticals
				
Change 3Q22 vs 3Q21:				
Reported	**(1%)**	**(1%)**	**(1%)**	**1%**
Organic[1]	**5%**	**4%**	**8%**	**5%**

Key drivers

Reported revenue change

Revenue	Vision Care	Surgical	Ophthalmic Pharmaceuticals
• Strong demand across key franchises	• Lumify® **7%** • BioTrue® **2%** • Ocuvite® + PreserVision® **14%**	• Growth in enVista® IOL • International launch LuxSmart™	• Vyzulta® TRx growth

1. This is a non-GAAP measure or non-GAAP ratio. See Slide 3 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

Consolidated

3Q22/YTD Revenue performance

	3Q22	3Q21	Reported	Organic[1]
Salix	$544M	$527M	3%	3%
International[2]	$250M	$271M	(8%)	10%
Solta Medical[2]	$72M	$74M	(3%)	4%
Diversified Products[2]	$238M	$290M	(18%)	(17%)
Neuro	$126M	$151M	(17%)	(15%)
Generics[2]	$26M	$49M	(47%)	(47%)
Ortho Dermatologics[2]	$61M	$67M	(9%)	(9%)
Dentistry[2]	$25M	$23M	9%	9%
Total Bausch Pharma + Solta[1]	$1,104M	$1,162M	(5%)	(1%)
Vision Care[2]	$598M	$605M	(1%)	4%
Surgical	$172M	$173M	(1%)	8%
Ophtho Pharmaceuticals[2]	$172M	$171M	1%	5%
Bausch+Lomb[2]	$942M	$949M	(1%)	5%
Total Bausch Health	$2,046M	$2,111M	(3%)	2%

	YTD22	YTD21	Reported	Organic[1]
Salix	$1,509M	$1,515M	0%	0%
International[2]	$727M	$890M	(18%)	7%
Solta Medical[2]	$201M	$219M	(8%)	(5%)
Diversified Products[2]	$722M	$850M	(15%)	(15%)
Neuro	$375M	$448M	(16%)	(16%)
Generics[2]	$96M	$131M	(27%)	(27%)
Ortho Dermatologics[2]	$178M	$198M	(10%)	(10%)
Dentistry[2]	$73M	$73M	0%	0%
Total Bausch Pharma + Solta[1]	$3,159M	$3,474M	(9%)	(3%)
Vision Care[2]	$1,747M	$1,717M	2%	7%
Surgical	$530M	$520M	2%	9%
Ophtho Pharmaceuticals[2]	$495M	$527M	(6%)	(3%)
Bausch+Lomb[2]	$2,772M	$2,764M	0%	5%
Total Bausch Health	$5,931M	$6,238M	(5%)	1%

1. This is a non-GAAP measure or non-GAAP ratio. See Slide 3 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.
2. Commencing in the first quarter of 2022, the Company operates in the following reportable segments: (i) Salix, (ii) International, (iii) Diversified Products, (iv) Solta Medical and (v) Bausch + Lomb. Also commencing in the first quarter of 2022, the Company moved certain products previously reported in the Dentistry business unit to the Ortho Dermatologics business unit and certain products previously reported in the Ortho Dermatologics business unit to the Generics business unit.

Consolidated

3Q22 GAAP financial results

	Three Months Ended		Favorable (Unfavorable)
	9.30.22	9.30.21	Reported
Revenues	$2,046M	$2,111M	(3%)
GAAP Gross Profit	$1,171M	$1,173M	0%
GAAP Gross Margin	57.2%	55.6%	160 bps
Selling, A&P	$448M	$459M	2%
GAAP G&A	$213M	$194M	(10%)
R&D	$133M	$121M	(10%)
GAAP Total Operating Expense	$794M	$774M	(3%)
GAAP Operating Income	$244M	$574M	(57%)
GAAP Net Income Attributable to Bausch Health Companies Inc.[1]	$399M	$188M	112%
GAAP EPS Attributable to Bausch Health Companies Inc.	$1.10	$0.52	
GAAP Cash Flow from Operations	($1,263M)	$564M	(324%)

1. Includes gain on extinguishment of debt of $570 million, net of third party fees in connection with the Exchange Offer.

Consolidated

3Q22 Non-GAAP financial results

	Three Months Ended		Favorable (Unfavorable)	
	9.30.22	9.30.21	Change	Constant Currency[1]
Revenues	$2,046M	$2,111M	(3%)	1%
Adj. Gross Profit[1,2]	$1,462M	$1,529M	(4%)	(2%)
Adj. Gross Margin[1]	71.5%	72.4%	(90 bps)	
Selling, A&P (same as reported)	$448M	$459M	2%	(2%)
Adj. G&A[1]	$177M	$141M	(26%)	(31%)
R&D (same as reported)	$133M	$121M	(10%)	(12%)
Total Adj. Operating Expense[1]	$758M	$721M	(5%)	(10%)
Adj. EBITA[1]	$704M	$808M	(13%)	(11%)
Adj. EBITDA Attributable to Bausch Health Companies Inc.[1]	$766M	$885M	(13%)	(12%)
Adj. Net Income Attributable to Bausch Health Companies Inc.[1] *Diluted Shares Outstanding*[2]	$277M *363.4M*	$417M *364.0M*	(34%)	
Adj. Cash Flows from Operations[1,4]	$9M	$382M	(98%)	

1. This is a non-GAAP measure or non-GAAP ratio. See Slide 3 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.
2. See Appendix for details on amortization and impairments of intangible assets.
3. This figure includes the dilutive impact of options and restricted stock units of approximately 932,000 and 4,448,000 common shares for the three months ended September 30, 2022 and 2021, respectively, which are excluded when calculating GAAP diluted loss per share because the effect of including the impact in this calculation would have been anti-dilutive.
4. Excludes legacy legal settlements (net of insurance recoveries), separation payments, separation-related payments, IPO payments and IPO-related payments, net cash provided by Amoun operating activities and third party fees paid in connection with the debt exchange transaction.

Consolidated

Balance sheet summary

	9.30.22	9.30.21	12.31.21
Cash, cash equivalents[1]	$497M	$1,904M	$2,119M
Revolving Credit Drawn[5]	$450M	$0M	$285M
Senior Secured Debt (principal amount)[2]	$13,388M	$7,673M	$7,958M
Senior Unsecured Debt (principal amount)[2]	$6,186M	$14,912M	$14,912M
Total Consolidated Debt (principal amount)[2]	$19,574M	$22,585M	$22,870M
Total Consolidated Debt (net of premiums and discounts)	$21,215M	$22,358M	$22,654M
Net Consolidated Debt (principal amount)[3]	$19,088M	$21,895M	$22,288M
TTM Adj. EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)[4]	$3,108M	$3,474M	$3,472M
TTM GAAP Net Income/Loss	$270M	($1,161M)	($937M)

1. Included in cash and cash equivalents as of December 31, 2021 and September 30, 2021 is $1,210 million of restricted cash previously paid into escrow in connection with the U.S. securities litigation, subject to an objector's appeal of the final court approval. The objector's period to file a petition expired on August 10, 2022 which means the securities litigation settlement and judgment has become "final". As a result, the Company's rights to the $1,210 million previously paid into escrow have been extinguished. Cash and cash equivalents as of December 31, 2021 includes $300 million in restricted cash paid into escrow funds under the terms of settlement agreements regarding the Glumetza Antitrust Litigation which were released from escrow in 2022. Restricted cash does not reduce net debt for any of the periods presented.
2. Debt balances shown at principal value. Senior secured debt figure is inclusive of revolving credit drawn (if any).
3. Net debt is net of unrestricted cash and cash equivalents.
4. This is a non-GAAP measure or non-GAAP ratio. See Slide 3 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.
5. Subsequent to Q3 2022, as of November 3, 2022, drew an additional net $60M on Bausch Pharma + Solta revolving credit facility.

Unconsolidated

Long term debt maturity profile

In millions USD

As of September 30, 2022[1,2]

$M	Total	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031
Restricted											
Revolver	$450	-	-	-	-	-	$450	-	-	-	-
Term Loan	$1,938	-	-	-	-	-	$1,938	-	-	-	-
Secured Notes	$6,976	-	-	-	$1,750	-	$1,500	$3,374	-	$352	-
Unsecured Notes	$6,187	-	-	-	$959	$748	$651	$686	$1,701	$869	$573
Mandatory Amortization	$531	$31	$125	$125	$125	$125	-	-	-	-	-
Unrestricted - Intermediate Holdco	$999	-	-	-	-	-	-	$999	-	-	-
Total, Bausch Pharma + Solta	**$17,080**	**$31**	**$125**	**$125**	**$2,834**	**$873**	**$4,538**	**$5,059**	**$1,701**	**$1,221**	**$573**
B+L Obligations	$2,494	$6	$25	$25	$25	$25	$2,388	-	-	-	-
Total Consolidated	**$19,574**	**$38**	**$150**	**$150**	**$2,859**	**$898**	**$6,926**	**$5,059**	**$1,701**	**$1,221**	**$573**

No debt maturities until 2025

1. Debt values are shown at principal value.
2. Subsequent to Q3 2022, as of November 3, 2022, drew an additional net $60M on Bausch Pharma + Solta revolving credit facility.

Unconsolidated

Bausch Pharma + Solta debt maturity profile[1,2,4]

As of September 30, 2022, in millions



TOTAL BAUSCH PHARMA + SOLTA DEBT

Total: $17.1B[2]

- **Restricted: $16.1B**
- **Unrestricted: $1.0B[3]**

$5.6B of existing notes exchanged; $2.5B debt reduction due to discount capture

Restricted debt down ~$3.5B in 3Q22 vs 2Q22

Push back near-term debt maturities

Interest savings of $65M

1. Debt values are shown at principal value.
2. Does not include ~$2.5B of Bausch + Lomb term loan entered into by Bausch + Lomb in connection with the closing of the Bausch + Lomb IPO.
3. Consists of $1B non-recourse debt issued by a wholly-owned unrestricted subsidiary, 1375209 B.C. Ltd., that owns 38.6% of the issued and outstanding shares of Bausch + Lomb.
4. Subsequent to Q3 2022, as of November 3, 2022, drew an additional net $60M on Bausch Pharma + Solta revolving credit facility.

3 FY 2022 guidance

Consolidated

Updated 2022 guidance[1,2]

All ranges are approximate and in USD

	Prior Guidance	Bausch + Lomb	Updated Guidance
Revenue[2]	$8.05B - $8.22B	($50M)	$8.00B - $8.17B
	Bausch + Lomb $3.75B - $3.80B		Bausch + Lomb $3.70B - $3.75B
	Bausch Pharma + Solta $4.30B - $4.42B		Bausch Pharma + Solta $4.30B - $4.42B
Adj. EBITDA (non-GAAP)[1,2]	$3.02B - $3.12B	($25M)	$2.99B - $3.09B
	Bausch + Lomb $740B - $780B		Bausch + Lomb $715B - $755B
	Bausch Pharma + Solta $2.28B - $2.34B		Bausch Pharma + Solta $2.28B - $2.34B

2022 Consolidated organic revenue growth[1,2] flat to +2%
2022 Bausch Pharma + Solta organic revenue [1,2] range of -3% to flat
2022 Bausch Pharma + Solta adj. cash flows from operations[1,2,3] ~$600 million

1. This is a non-GAAP measure or non-GAAP ratio. See Slide 3 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.
2. See Slide 2 for further information on forward-looking statements.
3. Excludes legacy legal settlements (net of insurance recoveries), separation payments, separation-related payments, IPO payments and IPO-related payments, net cash provided by Amoun operating activities and third party fees paid in connection with the debt exchange transaction.

Unconsolidated

Bausch Pharma + Solta full-year outlook[3]

All assumptions are approximate and in USD

	Prior Guidance	Current Guidance
Total Revenues	$4.30B - $4.42B	$4.30B - $4.42B
Adjusted EBITDA (non-GAAP)[1]	$2.28B - $2.34B	$2.28B - $2.34B

Key Assumptions	Prior Guidance	Current Guidance
Adjusted Gross Margin[1]	~80%	~80%
R&D Expense	~$225M	~$225M
Interest Expense[2]	~$1.4B	~$1.4B
Adj. Tax Rate (non-GAAP)[1]	~15%	~17%
Depreciation and Stock Based Comp	~$110M	~$110M
Capital Expenditures[4]	~$50M	~$50M

1. This is a non-GAAP measure or non-GAAP ratio. See Slide 3 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.
2. Interest expense current guidance has been calculated based on contractual principal and interest balances and includes amortization and write-down of deferred financing costs of $50M, without giving effect to the effect on interest expense of accounting for the premium recorded in connection with the September 2022 debt exchange.
3. See Slide 2 for further information on forward-looking statements.
4. Does not include impact of Bausch + Lomb IPO and proposed spin-off.

BAUSCH Health



4 Actions taken and path forward

2022 Bausch Pharma + Solta priorities[1]

1 Drive growth through operational excellence across the enterprise

- Accelerate growth engines of Salix and International
- Maximize cash-generation of Diversified Products
- Drive growth in Solta Medical

2 Intensify focus and operating rigor behind R&D and business development

- Advance our R&D pipeline with new rifaximin formulations and expand into new treatment areas

3 Cultivate a high-performance, results-oriented culture

- Establish a high performance, energized culture with a sense of urgency, ownership, and accountability
- Build a fit for purpose organization

4 Progress strategic alternatives

- Utilize cash from operations to improve leverage
- Continue to evaluate the distribution of Bausch + Lomb as Bausch Health considers all relevant factors, including patent litigation
- Flexibility to monetize up to additional ~8.7% of Bausch + Lomb
- Drive towards target net leverage ratio ~6.5x-6.7x

1. See Slide 2 for further information on forward-looking statements.

Key takeaways[1]

- Continue to drive growth, profitability and improve our balance sheet
- Vigorously defend our intellectual property and address patient needs with Xifaxan®
- Continue to evaluate potential options to maximize value for our stakeholders

1. See Slide 2 for further information on forward-looking statements.

BAUSCH Health

Powering up our potential

Appendix

Inventory in select U.S. businesses (QTD)[1]

Months on Hand						
Business Units	**As of June 30, 2021**	**As of September 30, 2021**	**Change 3Q21**	**As of June 30, 2022**	**As of September 30, 2022**	**Change 3Q22**
Ortho Dermatologics	0.98	1.25	0.27	1.19	1.18	(0.01)
Neurology	0.99	1.02	0.03	1.08	1.14	0.06
Salix	0.81	1.00	0.19	0.94	0.96	0.02

1.U.S. wholesale inventory

Inventory in select U.S. businesses (YTD)[1]

Months on Hand						
Business Units	**As of December 31, 2020**	**As of September 30, 2021**	**Change YTD 2021**	**As of December 31, 2021**	**As of September 30, 2022**	**Change YTD 2022**
Ortho Dermatologics	0.72	1.25	0.53	1.03	1.18	0.15
Neurology	0.56	1.02	0.46	1.17	1.14	(0.03)
Salix	0.74	1.00	0.26	0.99	0.96	(0.03)

1. U.S. wholesale inventory

Consolidated

YTD GAAP financial results

	Nine Months Ended		Favorable (Unfavorable)
	9.30.22	9.30.21	Reported
Revenues	$5,931M	$6,238M	(5%)
GAAP Gross Profit	$3,302M	$3,202M	3%
GAAP Gross Margin	55.7%	51.3%	440 bps
Selling, A&P	$1,356M	$1,347M	(1%)
GAAP G&A	$603M	$597M	(1%)
R&D	$387M	$348M	(11%)
GAAP Total Operating Expense	$2,346M	$2,292M	(2%)
GAAP Operating Income	$690M	$83M	731%
GAAP Net Income (Loss) Attributable to Bausch Health Companies Inc.[1]	$185M	($1,017M)	118%
GAAP EPS Attributable to Bausch Health Companies Inc.	$0.51	($2.84)	
GAAP Cash Flow from Operations	($1,203M)	$1,402M	(186%)

1. Includes gain of $570 million, net of third party fees of $25 million, in connection with the Exchange Offer.

Consolidated

YTD Non-GAAP financial results

	Nine Months Ended		Favorable (Unfavorable)	
	9.30.22	9.30.21	Reported	Constant Currency[1]
Revenues	$5,931M	$6,238M	(5%)	(2%)
Adj. Gross Profit [1,2]	$4,219M	$4,470M	(6%)	(3%)
Adj. Gross Margin [1]	71.1%	71.7%	(60 bps)	
Selling, A&P (same as reported)	$1,356M	$1,347M	(1%)	(4%)
Adj. G&A[1]	$472M	$444M	(6%)	(9%)
R&D (same as reported)	$387M	$348M	(11%)	(13%)
Adj. Operating Expense[1]	$2,215M	$2,139M	(4%)	(7%)
Adj. EBITA [1]	$2,004M	$2,331M	(14%)	(13%)
Adj. EBITDA Attributable to Bausch Health Companies Inc[1]	$2,199M	$2,563M	(14%)	(13%)
Adj. Net Income Attributable to Bausch Health Companies Inc[1] *Diluted Shares Outstanding[3]*	$741M *363.7M*	$1,139M *363.7M*	(35%)	
Adj. Cash Flow from Operations[1,4]	$513M	$1,378M	(63%)	

1. This is a non-GAAP measure or non-GAAP ratio. See Slide 3 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.
2. See Appendix for details on amortization and impairments of intangible assets.
3. This figure includes the dilutive impact of options and restricted stock units of approximately 1,906,000 and 5,221,000 common shares for the nine months ended September 30, 2022 and 2021, respectively, which are excluded when calculating GAAP diluted loss per share because the effect of including the impact in this calculation would have been anti-dilutive.
4. Excludes legacy legal settlements (net of insurance recoveries), separation payments, separation-related payments, IPO payments and IPO-related payments and net cash provided by Amoun operating activities.

Unconsolidated

Segment Profit[1]

3Q 2022	Salix	International	Solta Medical	Diversified Products	Total
Segment Revenue	$544M	$250M	$72M	$238M	$1,104M
Segment Profit[1]	$391M	$85M	$33M	$151M	$660M

3Q 2021	Salix	International	Solta Medical	Diversified Products	Total
Segment Revenue	$527M	$271M	$74M	$290M	$1,162M
Segment Profit[1]	$377M	$92M	$40M	$185M	$694M

1. Segment profit is based on operating income after the elimination of intercompany transactions, including between Bausch + Lomb and other segments. Certain costs, such as Amortization of intangible assets, Asset impairments, Goodwill impairments, Restructuring, integration, separation and IPO costs, Other (income) expense, net, and other corporate allocations are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance.

3Q22 Other financial information

In millions USD unless otherwise indicated

	Three Months Ended		Favorable (Unfavorable)	
	September 30, 2022	September 30, 2021	Reported	Constant Currency[1]
Cash Interest Expense	$374M	$333M	(12%)	(12%)
Net Interest Expense	$382M	$349M	(9%)	(9%)
Non-cash adjustments				
Depreciation	$45M	$44M	(2%)	(7%)
Non-cash share-based Comp	$33M	$33M	0%	0%
Additional cash items				
Contingent Consideration	$6M	$44M		
Milestones/License Agreements and Other Intangibles	$3M	$7M		
Restructuring and Other	$31M	$12M		
Capital Expenditures	$54M	$63M		
Adj. Tax Rate[1]	11.5%	9.0%		
GAAP Tax Rate	8.0%	11.3%		

1. This is a non-GAAP measure or non-GAAP ratio. See Slide 3 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

YTD Other financial information

In millions USD unless otherwise indicated

	Nine Months Ended		Favorable (Unfavorable)	
	September 30, 2022	September 30, 2021	Reported	Constant Currency[1]
Cash Interest Expense	$1,118M	$1,040M	(8%)	(8%)
Net Interest Expense	$1,149M	$1,077M	(7%)	(7%)
Non-cash adjustments				
Depreciation	$132M	$134M	1%	(2%)
Non-cash share-based Comp	$91M	$95M	4%	4%
Additional cash items				
Contingent Consideration	$20M	$93M		
Milestones/License Agreements and Other Intangibles	$22M	$13M		
Restructuring and Other	$79M	$37M		
Capital Expenditures	$152M	$191M		
Adj. Tax Rate[1]	11.5%	9.3%		
GAAP Tax Rate	13.3%	3.5%		

1. This is a non-GAAP measure or non-GAAP ratio. See Slide 3 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

3Q22 Non-GAAP adjustments EPS impact

In millions USD unless otherwise indicated

	Three Months Ended			
	September 30, 2022		September 30, 2021	
	Income (Expense)	Earnings per Share Impact	Income (Expense)	Earnings per share Impact
Net income (loss)	**$403**	**$1.11**	**$191**	**$0.52**
Non-GAAP adjustments:[1]				
Amortization of intangible assets	290	0.80	338	0.93
Goodwill impairments	119	0.33	-	-
Asset impairments, including loss on assets held for sale	1	-	18	0.05
Restructuring, integration, and transformation costs	13	0.04	3	0.01
Acquired in-process research and development costs	-	-	-	-
Acquisition-related costs and adjustments (excluding amortization of intangible assets)	4	0.01	8	0.02
(Gain) loss on extinguishment of debt	(570)	(1.57)	12	0.03
IT infrastructure investment	2	0.01	6	0.02
Separation costs, separation-related costs, IPO costs and IPO-related costs	27	0.07	41	0.11
Legal and other professional fees	4	0.01	11	0.03
(Gain) loss on sale of assets, net	-	-	21	0.06
Litigation and other matters	-	-	(212)	(0.58)
Other	-	-	-	-
Tax effect of non-GAAP adjustments	(2)	(0.01)	(17)	(0.05)
EPS difference between basic and diluted shares	-	-	-	-
Adjusted net income (non-GAAP)[1]	**291**	**-**	**420**	**-**
Adjusted net income attributable to noncontrolling interest (non-GAAP)[1]	(14)	(0.04)	(3)	(0.01)
Adjusted net income attributable to Bausch Health Companies Inc. (non-GAAP)[1]	**$277**		**$417**	

1. This is a non-GAAP measure or non-GAAP ratio. See Slide 3 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

YTD Non-GAAP adjustments EPS impact

In millions USD unless otherwise indicated

	Nine Months Ended			
	September 30, 2022		September 30, 2021	
	Income (Expense)	Earnings per Share Impact	Income (Expense)	Earnings per share Impact
Net income (loss)	**$198**	**$0.54**	**($1,009)**	**($2.81)**
Non-GAAP adjustments:[1]				
Amortization of intangible assets	902	2.48	1,055	2.90
Goodwill impairments	202	0.56	469	1.29
Asset impairments, including loss on assets held for sale	15	0.04	213	0.59
Restructuring, integration, and transformation costs	38	0.10	9	0.02
Acquired in-process research and development costs	-	-	3	0.01
Acquisition-related costs and adjustments (excluding amortization of intangible assets)	2	0.01	8	0.02
(Gain) loss on extinguishment of debt	(683)	(1.88)	62	0.17
IT infrastructure investment	10	0.03	17	0.05
Separation costs, separation-related costs, IPO costs and IPO-related costs	114	0.31	111	0.31
Legal and other professional fees	27	0.07	45	0.12
(Gain) loss on sale of assets, net	(3)	(0.01)	(2)	(0.01)
Litigation and other matters	7	0.02	320	0.88
Other	8	0.02	-	-
Tax effect of non-GAAP adjustments	(69)	(0.19)	(154)	(0.42)
EPS difference between basic and diluted shares	-	-	-	0.03
Adjusted net income (non-GAAP)[1]	**768**	**-**	**1,147**	**-**
Adjusted net income attributable to noncontrolling interest (non-GAAP)[1]	(27)	(0.07)	(8)	(0.02)
Adjusted net income attributable to Bausch Health Companies Inc. (non-GAAP)[1]	**$741**		**$1,139**	

1. This is a non-GAAP measure or non-GAAP ratio. See Slide 3 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

Q3 Reconciliation of reported operating income to adjusted EBITA (non-GAAP)[1]

In millions USD

	Q3 2022						
	Gross Profit	Gross Margin	Selling & Advertising	G&A and Other	R&D Expense	Operating Expense	Operating Income
GAAP operating income	**$1,171**	**57.2%**	**$448**	**$213**	**$133**	**$794**	**$244**
Amortization of intangible assets	290	14.2%				-	290
Goodwill impairments						-	119
Asset impairments, including loss on assets held for sale	1	0.0%				-	1
Restructuring, integration, and transformation costs				(10)		(10)	13
Acquired in-process research and development costs						-	-
Acquisition-related costs and adjustments (excluding amortization of intangible assets)				-		-	4
IT infrastructure investment				(2)		(2)	2
Separation costs, separation-related costs, IPO costs and IPO-related costs				(20)		(20)	27
Legal and other professional fees				(4)		(4)	4
(Gain) loss on sale of assets, net						-	-
Litigation and other matters						-	-
Other				-		-	-
Tax effect of non-GAAP adjustments						-	-
Adj EBITA (Non-GAAP)[1]	**$1,462**	**71.5%**	**$448**	**$177**	**$133**	**$758**	**$704**

	Q3 2021						
	Gross Profit	Gross Margin	Selling and Advertising	G&A and Other	R&D Expense	Operating Expense	Operating Income
GAAP operating income	**$1,173**	**55.6%**	**$459**	**$194**	**$121**	**$774**	**$574**
Amortization of intangible assets	338	16.0%				-	338
Goodwill impairments						-	-
Asset impairments, including loss on assets held for sale	18	0.9%				-	18
Restructuring, integration, and transformation costs						-	3
Acquired in-process research and development costs						-	-
Acquisition-related costs and adjustments (excluding amortization of intangible assets)						-	8
IT infrastructure investment				(6)		(6)	6
Separation costs, separation-related costs, IPO costs and IPO-related costs				(36)		(36)	41
Legal and other professional fees				(11)		(11)	11
(Gain) loss on sale of assets, net						-	21
Litigation and other matters						-	(212)
Other						-	-
Tax effect of non-GAAP adjustments						-	-
Adj EBITA (Non-GAAP)[1]	**$1,529**	**72.4%**	**$459**	**$141**	**$121**	**$721**	**$808**

1. This is a non-GAAP measure or non-GAAP ratio. See Slide 3 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

YTD Reconciliation of reported operating income to adjusted EBITA (non-GAAP)[1]

In millions USD

	September YTD 2022						
	Gross Profit	Gross Margin	Selling & Advertising	G&A and Other	R&D Expense	Operating Expense	Operating Income
GAAP operating income	**$3,302**	**55.7%**	**$1,356**	**$603**	**$387**	**$2,346**	**$690**
Amortization of intangible assets	902	15.2%				-	902
Goodwill impairments						-	202
Asset impairments, including loss on assets held for sale	15	0.3%				-	15
Restructuring, integration, and transformation costs				(10)		(10)	38
Acquired in-process research and development costs						-	-
Acquisition-related costs and adjustments (excluding amortization of intangible assets)						-	2
IT infrastructure investment				(10)		(10)	10
Separation costs, separation-related costs, IPO costs and IPO-related costs				(84)		(84)	114
Legal and other professional fees				(27)		(27)	27
(Gain) loss on sale of assets, net						-	(3)
Litigation and other matters						-	7
Other				-		-	-
Tax effect of non-GAAP adjustments						-	-
Adj EBITA (Non-GAAP)[1]	**$4,219**	**71.1%**	**$1,356**	**$472**	**$387**	**$2,215**	**$2,004**

	September YTD 2021						
	Gross Profit	Gross Margin	Selling and Advertising	G&A and Other	R&D Expense	Operating Expense	Operating Income
GAAP operating income	**$3,202**	**51.3%**	**$1,347**	**$597**	**$348**	**$2,292**	**$83**
Amortization of intangible assets	1,055	16.9%				-	1,055
Goodwill impairments						-	469
Asset impairments, including loss on assets held for sale	213	3.4%				-	213
Restructuring, integration, and transformation costs						-	9
Acquired in-process research and development costs						-	3
Acquisition-related costs and adjustments (excluding amortization of intangible assets)						-	8
IT infrastructure investment				(17)		(17)	17
Separation costs, separation-related costs, IPO costs and IPO-related costs				(91)		(91)	111
Legal and other professional fees				(45)		(45)	45
(Gain) loss on sale of assets, net						-	(2)
Litigation and other matters						-	320
Other						-	-
Tax effect of non-GAAP adjustments						-	-
Adj. EBITA (Non-GAAP)[1]	**$ 4,470**	**71.7%**	**$1,347**	**$444**	**$348**	**2,139**	**$2,331**

1. This is a non-GAAP measure or non-GAAP ratio. See Slide 3 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

Q3 & YTD Reconciliation of reported net income (loss) to EBITDA[1] and adjusted EBITDA[1]

In millions USD

	Three months ended September 30,		Nine months ended September 30,	
	2022	2021	2022	2021
Net income (loss) attributable to Bausch Health Companies Inc.	**$403**	**$191**	**$198**	**($1,009)**
Interest expense, net	382	349	1,149	1,077
Provision for (benefit from) income taxes	36	25	30	(36)
Depreciation and amortization	335	382	1,034	1,189
EBITDA (Non-GAAP)[1]	**1,156**	**947**	**2,411**	**1,221**
Adjustments:				
Goodwill impairments	119	-	202	469
Asset impairments, including loss on assets held for sale	1	18	15	213
Restructuring, integration, and transformation costs	13	3	38	9
Acquisition related costs and adjustments (excluding amortization of intangible assets)	4	8	2	8
(Gain) loss on extinguishment of debt	(570)	12	(683)	62
Share-based compensation	33	33	91	95
Separation cost, separation-related costs, IPO costs and IPO-related costs	27	41	114	111
Other adjustments:				
Litigation and other matters	-	(212)	7	320
IT infrastructure investment	2	6	10	17
Legal and other professional fees	4	11	27	45
(Gain) loss on sale of assets, net	-	21	(3)	(2)
Acquired in-process research and development costs	-	-	-	3
Other	-	-	8	-
Adjusted EBITDA (non-GAAP)[1]	**789**	**888**	**2,239**	**2,571**
Adjusted EBITDA attributable to noncontrolling interest (non-GAAP)[1]	(23)	(3)	(40)	(8)
Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)[1]	**$766**	**$885**	**$2,199**	**$2,563**

	Three months ended September 30,		Nine months ended September 30,	
	2022	2021	2022	2021
GAAP Net income attributable to noncontrolling interest	**($4)**	**($3)**	**($13)**	**($8)**
Noncontrolling interest portion of adjustments for				
Interest expense, net	(4)	-	(6)	-
(Benefit from) provision for income taxes	-	-	-	-
Depreciation and amortization	(11)	-	(17)	-
Share-based compensation	(2)	-	(2)	-
Other	(2)	-	(2)	-
Adjusted EBITDA attributable to noncontrolling interest (non-GAAP)[1]	**($23)**	**($3)**	**($40)**	**($8)**

1. This is a non-GAAP measure or non-GAAP ratio. See Slide 3 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

3Q22 reconciliation of reported revenue to organic revenue[1,2] and organic revenue growth[1,3]

	For Three Months Ended						Change in Reported Revenue		Change in Organic Revenue[1]	
	September 30, 2022			September 30, 2021						
	Revenue as reported	Changes in Exchange Rates[2]	Organic Revenue (Non-GAAP)[1]	Revenue as Reported	Divestitures and Disconti-nuations	Organic Revenue (Non-GAAP)[1]	Amount	Pct.	Amount	Pct.
Salix	$544		$544	$527		$527	$17	3%	$17	3%
International[3]	250	22	272	271	(23)	248	(21)	(8%)	24	10%
Solta Medical[3]	72	5	77	74	-	74	(2)	(3%)	3	4%
Neuro	126		126	151	(2)	149	(25)	(17%)	(23)	(15%)
Generics[3]	26		26	49		49	(23)	(47%)	(23)	(47%)
Ortho Dermatologics[3]	61		61	67		67	(6)	(9%)	(6)	(9%)
Dentistry[3]	25		25	23		23	2	9%	2	9%
Diversified Products[3]	238		238	290	(2)	288	(52)	(18%)	(50)	(17%)
Total Bausch Pharma+Solta revenues	**$1,104**	**$27**	**$1,131**	**$1,162**	**($25)**	**$1,137**	**($58)**	**(5%)**	**($6)**	**(1%)**
Vision Care	598	34	632	605		605	(7)	(1%)	27	4%
Surgical	172	13	185	173	(1)	172	(1)	(1%)	13	8%
Ophthalmic Pharmaceuticals	172	8	180	171		171	1	1%	9	5%
Total Bausch + Lomb[3] revenues	**$942**	**$55**	**$997**	**$949**	**($1)**	**$948**	**(7)**	**(1%)**	**49**	**5%**
Total Bausch Health revenues	**$2,046**	**$82**	**$2,128**	**$2,111**	**($26)**	**$2,085**	**($65)**	**(3%)**	**$43**	**2%**

1. This is a non-GAAP measure or non-GAAP ratio. See Slide 3 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.
2. The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.
3. See footnote 2 on slide 13 for further details regarding the realigned segment reporting structure and the conformed prior period presentation.

YTD reconciliation of reported revenue to organic revenue[1,2] and organic revenue growth[1,3]

	For Nine Months Ended						Change in Reported Revenue		Change in Organic Revenue[1]	
	September 30, 2022			September 30, 2021						
	Revenue as reported	Changes in Exchange Rates[2]	Organic Revenue (Non-GAAP)[1]	Revenue as Reported	Divestitures and Disconti-nuations	Organic Revenue (Non-GAAP)[1]	Amount	Pct.	Amount	Pct.
Salix	$1,509		$1,509	$1,515		$1,515	($6)	0%	($6)	0%
International[3]	727	49	776	890	(163)	727	(163)	(18%)	49	7%
Solta Medical[3]	201	7	208	219		219	(18)	(8%)	(11)	(5%)
Neuro	375		375	448	(2)	446	(73)	(16%)	(71)	(16%)
Generics[3]	96		96	131		131	(35)	(27%)	(35)	(27%)
Ortho Dermatologics[3]	178		178	198		198	(20)	(10%)	(20)	(10%)
Dentistry[3]	73		73	73		73	0	0%	0	0%
Diversified Products[3]	722		722	850	(2)	848	(128)	(15%)	(126)	(15%)
Total Bausch Pharma+Solta revenues	**$3,159**	**$56**	**$3,215**	**$3,474**	**($165)**	**$3,309**	**(315)**	**(9%)**	**($94)**	**(3%)**
Vision Care	1,747	82	1,829	1,717		1,717	30	2%	112	7%
Surgical	530	30	560	520	(7)	513	10	2%	47	9%
Ophthalmic Pharmaceuticals	495	18	513	527		527	(32)	(6%)	(14)	(3%)
Total Bausch + Lomb revenues	**$2,772**	**$130**	**$2,902**	**$2,764**	**($7)**	**$2,757**	**8**	**0%**	**145**	**5%**
Total Bausch Health revenues	**$5,931**	**$186**	**$6,117**	**$6,238**	**($172)**	**$6,066**	**($307)**	**(5%)**	**$51**	**1%**

1. This is a non-GAAP measure or non-GAAP ratio. See Slide 3 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.
2. The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.
3. See footnote 2 on slide 13 for further details regarding the realigned segment reporting structure and the conformed prior period presentation.

Reconciliation of reported cash provided by operating activities to adj. cash flows from operations (non-GAAP)[1]

In millions USD

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2022	2021	2022	2021
Cash (used in) provided by operating activities	($1,263)	$564	($1,203)	$1,402
Payments of legacy legal settlements, net of insurance proceeds	1,210	(201)	1,559	(71)
Payments of separation costs, separation-related costs, IPO costs, and IPO-related costs	31	28	126	81
Third party fees paid in connection with the Exchange Offer	31	-	31	-
Cash provided by Amoun operating activities	-	(9)	-	(34)
Adjusted cash flows from operations (non-GAAP)[1,2]	$9	$382	$513	$1,378

1. This is a non-GAAP measure or non-GAAP ratio. See Slide 3 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.
2. Excludes legacy legal settlements (net of insurance recoveries), separation payments, separation-related payments, IPO payments and IPO-related payments, net cash provided by Amoun operating activities and third party fees paid in connection with the debt exchange transaction.

Trailing twelve months adjusted EBITDA[1]

In millions USD

	Trailing Twelve Months Ended				
	Sep-22	Jun-22	Mar-22	Dec-21	Sep-21
Net income (loss)	**$270**	**$139**	**$ (396)**	**$(937)**	**$(1,161)**
Interest expense, net	1,491	1,458	1,413	1,419	1,454
Benefit from income taxes	(21)	(30)	(119)	(87)	(278)
Depreciation and amortization	1,397	1,444	1,501	1,552	1,617
EBITDA (non-GAAP)[2]	**3,137**	**3,011**	**2,399**	**1,947**	**1,632**
Adjustments:					
Asset impairments, including loss on assets held for sale	36	53	94	234	310
Goodwill impairments	202	0	-	469	469
Restructuring, integration, and transformation costs	47	37	18	18	8
Acquisition related costs and adjustments (excluding amortization of intangible assets)	5	9	23	11	30
(Gain) loss on extinguishment of debt	(683)	(101)	57	62	70
Share-based compensation	124	124	129	128	119
Separation costs, separation-related costs, IPO costs and IPO-related costs	167	181	169	164	138
Other adjustments:					
Litigation and other matters	43	(169)	355	356	615
IT infrastructure investment	20	24	27	27	22
Legal and other professional fees	36	43	52	54	56
(Gain) loss on sale of assets, net	(3)	18	21	(2)	(2)
Acquired in-process research and development costs	5	5	6	8	15
Other	15	15	13	7	1
Adjusted EBITDA (non-GAAP)[1]	**$3,151**	**$3,250**	**$3,363**	**$3,483**	**$3,483**
Adjusted net income attributable to noncontrolling interest (non-GAAP)[1]	(43)	(23)	(11)	(11)	(9)
Adjusted EBITDA attributable to Bausch Health Companies Inc. (non-GAAP)[1]	**$3,108**	**$3,227**	**$3,352**	**$ 3,472**	**$3,474**

1. This is a non-GAAP measure or non-GAAP ratio. See Slide 3 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

Non-GAAP Appendix

Description of Non-GAAP Financial Measures

To supplement the financial measures prepared in accordance with U.S. GAAP, the Company uses certain non-GAAP financial measures. These measures do not have any standardized meaning under GAAP and other companies may use similarly titled non-GAAP financial measures that are calculated differently from the way we calculate such measures. Accordingly, our non-GAAP financial measures may not be comparable to similar non-GAAP measures of other issuers. We caution investors not to place undue reliance on such non-GAAP measures, but instead to consider them with the most directly comparable GAAP measures. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation. They should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP.

Adjusted EBITDA and Adjusted EBITDA Attributable to Bausch Health

Adjusted EBITDA (non-GAAP) is Net income (loss) (its most directly comparable GAAP financial measure) adjusted for interest expense, net, (Benefit from) provision for income taxes, depreciation and amortization and certain other items described below. Adjusted EBITDA attributable to Bausch Health Companies Inc. (non-GAAP) is Adjusted EBITDA (non-GAAP) further adjusted to exclude the Adjusted EBITDA attributable to noncontrolling interest (non-GAAP) as defined below.

Management believes that Adjusted EBITDA (non-GAAP) and Adjusted EBITDA attributable to Bausch Health Companies Inc. (non-GAAP), along with the GAAP measures used by management, most appropriately reflect how the Company measures the business internally and sets operational goals and incentives. In particular, the Company believes that these metrics focus management on the Company's underlying operational results and business performance. As a result, the Company uses these metrics to assess the actual financial performance of the Company and to forecast future results as part of its guidance. Management believes these metrics are a useful measure to evaluate current performance. These metrics are intended to show our unleveraged, pre-tax operating results and therefore reflects our financial performance based on operational factors. In addition, cash bonuses for the Company's executive officers and other key employees are based, in part, on the achievement of certain Adjusted EBITDA (non-GAAP) targets.

Adjusted EBITDA (non-GAAP) is Net income (loss) (its most directly comparable GAAP financial measure) adjusted for interest expense, net, (Benefit from) provision for income taxes, depreciation and amortization and the following items:

Restructuring and integration costs: The Company has incurred restructuring costs as it implemented certain strategies, which involved, among other things, improvements to its infrastructure and operations, internal reorganizations and impacts from the divestiture of assets and businesses. With regard to infrastructure and operational improvements which the Company has taken to improve efficiencies in the businesses and facilities, these tend to be costs intended to right size the business or organization that fluctuate significantly between periods in amount, size and timing, depending on the improvement project, reorganization or transaction. The Company believes that the adjustments of these items provide supplemental information with regard to the sustainability of the Company's operating performance, allow for a comparison of the financial results to historical operations and forward-looking guidance and, as a result, provide useful supplemental information to investors.

Asset Impairments, including loss on assets held for sale: The Company has excluded the impact of impairments of finite-lived and indefinite-lived intangible assets, as well as impairments of assets held for sale, as such amounts are inconsistent in amount and frequency and are significantly impacted by the timing and/or size of acquisitions and divestitures. The Company believes that the adjustments of these items correlate with the sustainability of the Company’s operating performance. Although the Company excludes impairments of intangible assets and assets held for sale from measuring the performance of the Company and the business, the Company believes that it is important for investors to understand that intangible assets contribute to revenue generation.

Goodwill Impairments: The Company excludes the impact of goodwill impairments. When the Company has made acquisitions where the consideration paid was in excess of the fair value of the net assets acquired, the remaining purchase price is recorded as goodwill. For assets that we developed ourselves, no goodwill is recorded. Goodwill is not amortized but is tested for impairment. The amount of goodwill impairment is measured as the excess of a reporting unit’s carrying value over its fair value. Management excludes these charges in measuring the performance of the Company and the business.

Share-based compensation: The Company has excluded costs relating to share-based compensation. The Company believes that the exclusion of share-based compensation expense assists investors in the comparisons of operating results to peer companies. Share-based compensation expense can vary significantly based on the timing, size and nature of awards granted.

Non-GAAP Appendix

Acquisition-related costs and adjustments excluding amortization of intangible assets: The Company has excluded the impact of acquisition-related contingent consideration non-cash adjustments due to the inherent uncertainty and volatility associated with such amounts based on changes in assumptions with respect to fair value estimates, and the amount and frequency of such adjustments is not consistent and is significantly impacted by the timing and size of the Company's acquisitions, as well as the nature of the agreed-upon consideration. In addition, the Company excludes the impact of acquisition-related costs and fair value inventory step-up resulting from acquisitions as the amounts and frequency of such costs and adjustments are not consistent and are impacted by the timing and size of its acquisitions.

Gain (Loss) on extinguishment of debt: The Company has excluded gain (loss) on extinguishment of debt as this represents a cost of refinancing our existing debt and is not a reflection of our operations for the period. Further, the amount and frequency of such charges are not consistent and are significantly impacted by the timing and size of debt financing transactions and other factors in the debt market out of management's control.

Separation and IPO costs and separation-related and IPO-related costs: The Company has excluded certain costs incurred in connection with activities taken to: (i) separate the eye-health and the Solta aesthetic medical device businesses from the remainder of the Company and (ii) register the eye-health and the Solta aesthetic medical device businesses as independent publicly traded entities. Separation and IPO costs are incremental costs directly related to effectuating the separation of the eye-health business and the initial public offering ("IPO") of the Solta aesthetic medical device business (the "Solta IPO"), which has now been suspended, and include, but are not limited to, legal, audit and advisory fees, talent acquisition costs and costs associated with establishing a new board of directors and related board committees. Separation-related and IPO-related costs are incremental costs indirectly related to the separation of the eye-health business and the Solta IPO and include, but are not limited to, IT infrastructure and software licensing costs, rebranding costs and costs associated with facility relocation and/or modification. As these costs arise from events outside of the ordinary course of continuing operations, the Company believes that the adjustments of these items provide supplemental information with regard to the sustainability of the Company's operating performance, allow for a comparison of the financial results to historical operations and forward-looking guidance and, as a result, provide useful supplemental information to investors.

Other Non-GAAP adjustments: The Company has excluded certain other amounts, including legal and other professional fees incurred in connection with legal and governmental proceedings, investigations and information requests regarding certain of our legacy distribution, marketing, pricing, disclosure and accounting practices, litigation and other matters, and net (gain) loss on sales of assets. The Company has also excluded expenses associated with in-process research and development, as these amounts are inconsistent in amount and frequency and are significantly impacted by the timing, size and nature of acquisitions. Furthermore, as these amounts are associated with research and development acquired, the Company does not believe that they are a representation of the Company's research and development efforts during any given period. The Company has also excluded IT infrastructure investment, that are the result of other, non-comparable events to measure operating performance. These events arise outside of the ordinary course of continuing operations. Given the unique nature of the matters relating to these costs, the Company believes these items are not normal operating expenses. For example, legal settlements and judgments vary significantly, in their nature, size and frequency, and, due to this volatility, the Company believes the costs associated with legal settlements and judgments are not normal operating expenses. In addition, as opposed to more ordinary course matters, the Company considers that each of the recent proceedings, investigations and information requests, given their nature and frequency, are outside of the ordinary course and relate to unique circumstances. The Company believes that the exclusion of such out-of-the-ordinary-course amounts provides supplemental information to assist in the comparison of the financial results of the Company from period to period and, therefore, provides useful supplemental information to investors. However, investors should understand that many of these costs could recur and that companies in our industry often face litigation.

The Company has also excluded certain other costs including settlement costs associated with the conversion of a portion of the Company's defined benefit plan in Ireland to a defined contribution plan. The Company excluded these costs as this event is outside of the ordinary course of continuing operations and is infrequent in nature.

Prior to 2022, the Company had excluded expenses associated with acquired in-process research and development costs ("IPR&D"), as these amounts are inconsistent in amount and frequency and are significantly impacted by the timing, size and nature of acquisitions. Beginning in 2022, the Company no longer excludes IPR&D prospectively. The Company is making this change to align with views expressed by members of the staff of the SEC. The Company believes these costs are not material for the periods presented.

Adjusted EBITDA attributable to Bausch Health Companies Inc. (non-GAAP) is Adjusted EBITDA (non-GAAP) further adjusted to exclude the Adjusted EBITDA attributable to noncontrolling interest (non-GAAP). Adjusted EBITDA attributable to noncontrolling interest (non-GAAP) is Net income attributable to noncontrolling interest (its most directly comparable GAAP financial measure) adjusted for the portion of the adjustments described above attributable to noncontrolling interest.

Non-GAAP Appendix

Adjusted Net Income and Adjusted Net Income Attributable to Bausch Health

Adjusted net income (loss) (non-GAAP) is Net Income (its most directly comparable GAAP financial measure), adjusted for restructuring and integration costs, acquired in-process research and development costs, (gain) loss on extinguishment of debt, asset impairments (including (gain) loss on assets held for sale), acquisition-related adjustments, excluding amortization, separation and IPO costs and separation-related and IPO-related costs and other non-GAAP charges as these adjustments are described above, and amortization of intangible assets as described below:

Amortization of intangible assets: The Company has excluded the impact of amortization of intangible assets, as such amounts are inconsistent in amount and frequency and are significantly impacted by the timing and/or size of acquisitions. The Company believes that the adjustments of these items correlate with the sustainability of the Company's operating performance. Although the Company excludes the amortization of intangible assets from its non-GAAP expenses, the Company believes that it is important for investors to understand that such intangible assets contribute to revenue generation. Amortization of intangible assets that relate to past acquisitions will recur in future periods until such intangible assets have been fully amortized. Any future acquisitions may result in the amortization of additional intangible assets.

Adjusted net income attributable to Bausch Health Companies Inc. (non-GAAP) is Adjusted net income (non-GAAP) further adjusted to exclude the Adjusted net income attributable to noncontrolling interest (non-GAAP). Adjusted net income attributable to noncontrolling interest (non-GAAP) is Net income attributable to noncontrolling interest (its most directly comparable GAAP financial measure) adjusted for the portion of the adjustments described above attributable to noncontrolling interest.

Historically, management has used Adjusted net income (loss) (non-GAAP) (the most directly comparable GAAP financial measure for which is GAAP net income (loss)) for strategic decision making, forecasting future results and evaluating current performance. This non-GAAP measure excludes the impact of certain items (as described above) that may obscure trends in the Company's underlying performance. By disclosing this non-GAAP measure, it is management's intention to provide investors with a meaningful, supplemental comparison of the Company's operating results and trends for the periods presented. Management believes that this measure is also useful to investors as such measure allowed investors to evaluate the Company's performance using the same tools that management uses to evaluate past performance and prospects for future performance. Accordingly, the Company believes that Adjusted net income (non-GAAP) is useful to investors in their assessment of the Company's operating performance. It is also noted that, in recent periods, our GAAP net income (loss) was significantly lower than our Adjusted net income (non-GAAP). Commencing in 2017, management of the Company identified and began using certain new primary financial performance measures to assess the Company's financial performance. In addition, a subsequent to the Bausch + Lomb IPO, the Company began presenting Adjusted net income (non-GAAP) attributable to Bausch Health Companies Inc. may be useful to investors in their assessment of the Company and its performance.

Organic Growth/Change and Organic Revenue

Organic revenue and organic revenue change are non-GAAP measures. Non-GAAP measures are not standardized measures under the financial reporting framework used to prepare the Company's financial statements and might not be comparable to similar financial measures disclosed by other issuers.

Organic revenue and change in organic revenue (non-GAAP), are defined as GAAP Revenue and changes in GAAP revenue (the most directly comparable GAAP financial measures), adjusted for changes in foreign currency exchange rates (if applicable) and excluding the impact of recent acquisitions, divestitures and discontinuations, as defined further below. Organic revenue (non-GAAP) is impacted by changes in product volumes and price. The price component is made up of two key drivers: (i) changes in product gross selling price and (ii) changes in sales deductions. The Company uses organic revenue (non-GAAP) and organic revenue changes (non-GAAP) to assess performance of its reportable segments, and the Company in total, The Company believes that providing these measures is useful to investors as they provide a supplemental period-to-period comparison.

The adjustments to GAAP Revenue and changes in GAAP revenue to determine Organic Revenue (non-GAAP) and changes in Organic Revenue (non-GAAP) are as follows:

Foreign currency exchange rates: Although changes in foreign currency exchange rates are part of our business, they are not within management's control. Changes in foreign currency exchange rates, however, can mask positive or negative trends in the business. The impact of changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.

Non-GAAP Appendix

Acquisitions, divestitures and discontinuations: In order to present period-over-period organic revenue (non-GAAP) growth/change on a comparable basis, revenues associated with acquisitions, divestitures and discontinuations are adjusted to include only revenues from those businesses and assets owned during both periods. Accordingly, organic revenue and organic growth/change exclude from the current period, revenues attributable to each acquisition for twelve months subsequent to the day of acquisition, as there are no revenues from those businesses and assets included in the comparable prior period. Organic revenue and organic growth/change exclude from the prior period, all revenues attributable to each divestiture and discontinuance during the twelve months prior to the day of divestiture or discontinuance, as there are no revenues from those businesses and assets included in the comparable current period.

Adjusted EBITA and Adjusted EBITA Margin

Adjusted EBITA represents Operating income (loss) (its most directly comparable GAAP financial measure) adjusted to exclude amortization, fair value adjustments to inventory in connection with business combinations and integration related inventory charges and technology transfer costs, restructuring and integration costs, asset impairments, goodwill impairments, acquisition related costs, separation costs, IPO costs, separation-related costs, IPO-related costs and certain other non-GAAP charges as discussed under “Other Non-GAAP charges” above. Adjusted EBITA Margin (non-GAAP) is Adjusted EBITA (non-GAAP) divided by Revenues. The most directly comparable GAAP financial measure is operating income margin, which is Operating income (loss) divided by Revenues. On a segment basis, Adjusted EBITA represents Segment profit (its most directly comparable GAAP financial measure) adjusted to exclude the items above, as applicable.

Management believes that Adjusted EBITA (non-GAAP) and Adjusted EBITA Margin (non-GAAP), along with the GAAP measures used by management, appropriately reflect how the Company measures the business internally and sets operational goals for each of its businesses. In particular, the Company believes that Adjusted EBITA (non-GAAP) and Adjusted EBITA Margin (non-GAAP) focuses management on the Company’s underlying operational results and segment performance. As a result, the Company uses Adjusted EBITA (non-GAAP) and Adjusted EBITA Margin (non-GAAP) to assess the actual financial performance of each segment and to forecast future results as part of its guidance.

The Company believes that Adjusted EBITA (non-GAAP) and Adjusted EBITA Margin (non-GAAP) are useful to investors as they provide consistency and comparability with our past financial performance and facilitates period-to-period comparisons of the Company’s profitability and the profitability of our segments as they eliminate the effects of certain cash and non-cash charges, which given their nature and frequency, are outside the ordinary course and relate to unique circumstances.

Adjusted Gross Profit/Adjusted Segment Gross Profit and Adjusted Gross Margin/Adjusted Segment Gross Margin

Adjusted gross profit (non-GAAP)/Adjusted segment gross profit (non-GAAP) represents gross profit (its most directly comparable GAAP financial measure) adjusted for Other revenues, Cost of other revenues, Amortization of intangible assets and fair value adjustments to inventory in connection with business combinations. In accordance with GAAP, Gross profit represents total Revenues less Costs of goods sold (excluding amortization of intangible assets) less Cost of other revenues less Amortization of intangible assets. Adjusted gross margin (non-GAAP)/Adjusted segment gross margin (non-GAAP) (the most directly comparable GAAP financial measure for which is gross margin) represents Adjusted gross profit (non-GAAP)/Adjusted segment gross profit (non-GAAP) divided by Product revenues.

Adjusted gross profit (non-GAAP)/Adjusted segment gross profit (non-GAAP) and Adjusted gross margin (non-GAAP)/Adjusted segment gross profit margin (non-GAAP) are measures used by management to understand and evaluate each segment’s pricing strategy, strength of product portfolio, ability to control product costs and the success of its go-to-market strategies. Adjusted gross profit (non-GAAP)/Adjusted segment gross profit (non-GAAP) and Adjusted gross margin (non-GAAP)/Adjusted segment gross profit margin (non-GAAP) facilitates period-to-period comparisons of each segment’s ability to generate cash flows from sales, as these measures eliminate the effects of amortization of intangible assets and fair value adjustments to inventory in connection with business combinations, which are a non-cash charges.

The Company believes that Adjusted gross profit (non-GAAP)/Adjusted segment gross profit (non-GAAP) and Adjusted gross margin (non-GAAP)/Adjusted segment gross profit margin (non-GAAP) are useful to investors as they provide consistency and comparability with our past financial performance and facilitate period-to-period comparisons of each segments’ ability to generate incremental cash flows from its revenues as these measures eliminate the effects of amortization of intangible assets and fair value adjustments to inventory in connection with business combinations, which are a non-cash charges that can be impacted by, among other things, the timing and magnitude of acquisitions, which given their nature and frequency, are outside the ordinary course and relate to unique circumstances.

.

Non-GAAP Appendix

Adjusted SG&A Expenses and Adjusted G&A Expenses

Adjusted SG&A expenses (non-GAAP) represents selling, general and administrative expenses ("SG&A expenses") (its most directly comparable GAAP financial measure) and Adjusted G&A expenses (non-GAAP) represents general and administrative expenses ("G&A expenses") (its most directly comparable GAAP financial measure), each adjusted to exclude separation-related costs, IPO-related costs and certain costs primarily related to legal and other professional fees relating to legal and governmental proceedings, investigations and information requests respecting certain of our distribution, marketing, pricing, disclosure and accounting practices and separation-related and IPO-related costs. See the discussion under "Other Non-GAAP charges" above.

Management uses Adjusted SG&A expenses (non-GAAP) and Adjusted G&A (non-GAAP), along with GAAP measures, as a supplemental measure for period-to-period comparison to understand and evaluate each segment's ability to control costs and direct additional cash investments in each business.

The Company believes that Adjusted SG&A (non-GAAP) and Adjusted G&A (non-GAAP) are useful to investors as they provide consistency and comparability with our past financial performance and facilitates period-to-period comparisons of our SG&A expenses, G&A expenses and operations, as these measures eliminate the effects of separation-related costs, IPO-related costs and legal and other professional fees which given their nature and frequency, are outside the ordinary course and relate to unique circumstances.

Total Adjusted Operating Expenses

Total Adjusted Operating Expenses (non-GAAP) represents operating expenses (its most directly comparable GAAP financial measure) adjusted to exclude restructuring and integration costs, asset impairments, including loss on assets held for sale, goodwill impairments, acquisition related costs and adjustments excluding amortization of intangible assets, separation costs, IPO costs, separation-related costs, IPO-related costs and certain other non-GAAP charges as discussed under "Other Non-GAAP charges" above.

Management believes that Total Adjusted Operating Expenses (non-GAAP), along with the GAAP and non-GAAP measures used by management, provide a supplemental measure for period-to-period comparison to understand and evaluate its ability manage and control its costs, assess the actual financial performance of the Company and to forecast future results as part of its guidance. Management believes that Total Adjusted Operating Expenses (non-GAAP) is a useful measure to evaluate current performance amounts.

The Company believes that Total Adjusted Operating Expenses (non-GAAP) is useful to investors as it provides consistency and comparability with our past financial performance and facilitates period-to-period comparisons of our operating expenses as Total Adjusted Operating Expenses eliminates the effects of certain cash and non-cash charges, which given their nature and frequency, are outside the ordinary course and relate to unique circumstances which are substantially outside of management's control.

Adjusted Cash Flows from Operations

Adjusted cash flows from operations (non-GAAP) is Cash generated from operations (its most directly comparable GAAP financial measure) adjusted for: (i) payments of legacy legal settlements, net of insurance proceeds, (ii) payments for separation costs, IPO costs, separation-related costs, and IPO-related costs, (iii) Amoun Cash Flow from Operations in accordance to the terms related to the deal; and (iv) fees paid in connection with the debt exchange transaction

Management believes that Adjusted cash flows from operations (non-GAAP), along with the GAAP and non-GAAP measures used by management, most appropriately reflect how the Company measures the business internally. The Company uses adjusted cash flows from operations (non-GAAP) both to assess the actual financial performance of the Company and to forecast future results as part of its guidance. Management believes adjusted cash flows from operations (non-GAAP) is a useful measure to evaluate current performance amounts.

As these payments arise from events outside of the ordinary course of continuing operations as discussed above, the Company believes that the adjustments of these items provide supplemental information with regard to the sustainability of the Company's cash from operations, allow for a comparison of the financial results to historical operations and forward-looking guidance and, as a result, provide useful supplemental information to investors.

Non-GAAP Appendix

Constant Currency

Changes in the relative values of non-U.S. currencies to the U.S. dollar may affect the Company's financial results and financial position. To assist investors in evaluating the Company's performance, we have adjusted for foreign currency effects. Constant currency impact is determined by comparing 2022 reported amounts adjusted to exclude currency impact, calculated using 2021 monthly average exchange rates, to the actual 2021 reported amounts.

Adjusted Tax Rate

Adjusted Tax Rate (the most directly comparable financial measure for which is our GAAP tax rate) includes the tax impact of the various non-GAAP adjustments used in calculating our non-GAAP measures. However, due to the differences in the tax treatment of items excluded from non-GAAP earnings, our adjusted tax rate will differ from our GAAP tax rate and from our actual tax liabilities.